MYD88 and primary central nervous system lymphoma: It could mediate signals downstream of MYD88 and CD79B. Therefore, ibrutinib is a promising drug in PCNSL and has shown antitumor in preclinical PCNSL models as well as patients with relapsed/refractory PCNSL.10, 11, 12, 18